Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Topex’s superficial x-ray therapy system offers alternative to surgery for skin cancers

Topex : 17 April, 2008  (New Product)
Topex of Danbury, Connecticut, US is helping to fight skin cancer with the introduction of its SRT 100 low energy or superficial x-ray therapy system specially designed for skin cancer treatment procedures.
The new system provides an alternative to surgery for treating basal cell and squamous cell carcinomas, especially for primary lesions requiring difficult or extensive surgery with sensitive structures in the head and neck regions - the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear that would otherwise lead to a poor cosmetic outcome.

These treatment procedures do not require the use of anaesthetics and eliminates the need for skin grafting when surgery could result in a less than desirable cosmetic outcome.

The procedure also benefits those patients who have a fear of surgery or a needle phobia, for those patients who have contraindications for reconstructive surgery that are taking anti-coagulants and blood thinners and for those that cannot tolerate general anaesthesia.

More than 1 million new skin cancer cases are diagnosed annually and increasing at a rate of four percent per year. Increased exposure to the sun without skin protection and a decreasing natural ozone layer are cited as the chief causes of this increase - a problem estimated at over $1 billion in annual medical treatment expenses. More than 80 percent of skin cancers occur in the head and neck regions with 50 percent occurring in those over 60 years of age. The over 60 population is rising and is expected to double in size by 2025.

The incidence of skin cancer has steadily increased over the past 75 years. During the 1930s, 1 in 1500 developed skin cancer. In 1960, the rate had risen to 1 in 600 and in 2000, the rate increased to 1 in 66. The National Cancer Institute estimates that one out of seven is now at risk for developing some form of skin cancer during their lifetime. Increased exposure to the sun without skin protection and a decreasing natural ozone layer are cited as the chief causes of this increase.

The clinical objective of Topex is to effectively treat skin cancer through non-invasive therapeutic X-ray procedures with improved cosmetic outcomes. With this objective, the Topex system provides advantages to patients, physicians, healthcare providers and insurance payers that include the following:
For the Patient - The procedure is accurate, safe and pain-free. The Topex system provides patients an alternative to surgery.

For the Physician - Superficial X-ray therapy is a proven procedure for treating skin cancer and has a lower potential for cosmetic issues combined with a high cure rate history of effectiveness.

For the Practice - As a dedicated system to treat skin cancer, the medical practice benefits from increased patient referrals. The system has no special environmental requirements such as special power sources or waste disposal. The compact design requires minimal floor space with mobility for patient treatment flexibility.

For the Payer - Superficial X-ray therapy provides an alternative to surgery and a high cure rate history of effectiveness. The insurance industry, including Medicare part B widely accepts this procedure for reimbursement.

Topex began product development during 2003 after consultation with industry experts and the completion of a market needs analysis. The company was incorporated in the state of Connecticut during 2004 and in 2007 received FDA approval, European CE Mark and ISO 13484 Certification meeting the requirements for quality manufacturing standards, performance consistency and internal process documentation requirements.

Since receiving all required certifications, Topex has been developing a global dealer/distribution network and now has several systems operating in the USA, South Africa, Europe and Australia.

Topex was founded by Anthony Pellegrino, also the founder of Lorad, which became the worldwide leader in women's health mammography breast imaging and stereotactic biopsy systems.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo